Previvo Genetics, Inc.

previvo.com

Previvo is a medical device company that utilizes patented technology to facilitate the capture of embryos without the processes used with In Vitro Fertilization (IVF). Previvo Uterine Lavage is a novel medical device that enables the recovery of in vivo (inside the body) embryos from the uterus of a woman. The medical device includes an intrauterine Lavage Catheter, a Lavage Controller, and a collection system. Once embryos are recovered, they can be biopsied and screened for specific genetic diseases to assist families with fertility planning. Previvo Uterine Lavage offers a potentially more natural and healthier alternative to in vitro Fertilization (IVF) embryo collection processes.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

HEALIVA® ACQUIRES CRITICAL CELL THERAPY MANUFACTURING ASSETS FROM B. BRAUN

Healiva | November 22, 2022

news image

Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of critical manufacturing assets from B. Braun Medical AG Switzerland, an affiliate of German medical and pharmaceutical device company, B. Braun SE. The acquisition includes a qualified cell bank, which is essential for the GMP-compliant manufacturing of Healiva’s first cell therapy product, EpiDex®: an autologous epidermis de...

Read More

Cell and Gene Therapy

FULGENT GENETICS ANNOUNCES STRATEGIC INVESTMENT IN SPATIAL GENOMICS

Fulgent Genetics, Inc. | February 24, 2022

news image

Fulgent Genetics, Inc. a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a strategic investment in Spatial Genomics, Inc. a leading developer of sequential fluorescence in situ hybridization technology. Fulgent Genetics is investing up to $40 million to lead Spatial Genomics’ Series A financing, which totals approximately $56 million and also includes investments by 12 West Cap...

Read More

QUENCH BIO EMERGES WITH $50M TO TREAT SEVERE INFLAMMATORY DISEASES

Labiotech.eu | January 27, 2020

news image

Most treatments for inflammatory diseases have single targets, such as an inflammation-promoting cytokine or a protein complex called an inflammasome. Quench Bio is taking aim at a family of proteins involved in inflammatory cell death—and it’s picked up $50 million to do so. Seeded by Atlas Venture and Arix Bioscience and incubated at Atlas since its inception in 2018, Quench's first target is gasdermin D, the best understood member of the gasdermin family of proteins. With its ...

Read More

Industrial Impact

VERANTOS NAMED "BIOINFORMATICS COMPANY OF THE YEAR" BY BIOTECH BREAKTHROUGH

BioTech Breakthrough, Verantos | October 28, 2021

news image

Verantos, the market leader in high-validity real-world evidence (RWE) generation, today announced it has been named "BioInformatics Company of the Year" in the inaugural BioTech Breakthrough Awards program conducted by BioTech Breakthrough. This independent market intelligence organization evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe. The Verantos real-world evidence (RWE) platform leverages data sc...

Read More
news image

Cell and Gene Therapy

HEALIVA® ACQUIRES CRITICAL CELL THERAPY MANUFACTURING ASSETS FROM B. BRAUN

Healiva | November 22, 2022

Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of critical manufacturing assets from B. Braun Medical AG Switzerland, an affiliate of German medical and pharmaceutical device company, B. Braun SE. The acquisition includes a qualified cell bank, which is essential for the GMP-compliant manufacturing of Healiva’s first cell therapy product, EpiDex®: an autologous epidermis de...

Read More
news image

Cell and Gene Therapy

FULGENT GENETICS ANNOUNCES STRATEGIC INVESTMENT IN SPATIAL GENOMICS

Fulgent Genetics, Inc. | February 24, 2022

Fulgent Genetics, Inc. a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a strategic investment in Spatial Genomics, Inc. a leading developer of sequential fluorescence in situ hybridization technology. Fulgent Genetics is investing up to $40 million to lead Spatial Genomics’ Series A financing, which totals approximately $56 million and also includes investments by 12 West Cap...

Read More
news image

QUENCH BIO EMERGES WITH $50M TO TREAT SEVERE INFLAMMATORY DISEASES

Labiotech.eu | January 27, 2020

Most treatments for inflammatory diseases have single targets, such as an inflammation-promoting cytokine or a protein complex called an inflammasome. Quench Bio is taking aim at a family of proteins involved in inflammatory cell death—and it’s picked up $50 million to do so. Seeded by Atlas Venture and Arix Bioscience and incubated at Atlas since its inception in 2018, Quench's first target is gasdermin D, the best understood member of the gasdermin family of proteins. With its ...

Read More
news image

Industrial Impact

VERANTOS NAMED "BIOINFORMATICS COMPANY OF THE YEAR" BY BIOTECH BREAKTHROUGH

BioTech Breakthrough, Verantos | October 28, 2021

Verantos, the market leader in high-validity real-world evidence (RWE) generation, today announced it has been named "BioInformatics Company of the Year" in the inaugural BioTech Breakthrough Awards program conducted by BioTech Breakthrough. This independent market intelligence organization evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe. The Verantos real-world evidence (RWE) platform leverages data sc...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us